{"id":2104,"date":"1994-01-01T00:00:00","date_gmt":"1994-01-01T00:00:00","guid":{"rendered":"https:\/\/www.deberes.net\/tesis\/1994\/01\/01\/comparacion-entre-la-combinacion-ciclofosfamida-4-epiadriamicina-fluorouracilo-cef-y-ciclofosfamida-mitoxantrone-fluorouracilo-cnf-en-el-carcinoma-avanzado-de-la-mujer\/"},"modified":"1994-01-01T00:00:00","modified_gmt":"1994-01-01T00:00:00","slug":"comparacion-entre-la-combinacion-ciclofosfamida-4-epiadriamicina-fluorouracilo-cef-y-ciclofosfamida-mitoxantrone-fluorouracilo-cnf-en-el-carcinoma-avanzado-de-la-mujer","status":"publish","type":"post","link":"https:\/\/www.deberes.net\/tesis\/ciencias-medicas\/comparacion-entre-la-combinacion-ciclofosfamida-4-epiadriamicina-fluorouracilo-cef-y-ciclofosfamida-mitoxantrone-fluorouracilo-cnf-en-el-carcinoma-avanzado-de-la-mujer\/","title":{"rendered":"\u00abcomparacion entre la combinacion ciclofosfamida 4-epiadriamicina fluorouracilo (cef) y ciclofosfamida mitoxantrone. fluorouracilo (cnf) en el carcinoma avanzado de la mujer\u00bb."},"content":{"rendered":"<h2>Tesis doctoral de <strong> Emilio Esteban Gonzalez <\/strong><\/h2>\n<p>Desde diciembre de 1987 a junio de 1993, 151 pacientes fueron estratificadas segun la localizacion metastasica dominante asi como por el estado general siguiendo la escala de karnofsky y aleatorizadas para recibir:  cliclofosfamida 100 mg\/m2 p.O dia 1 a 14 + fluorouracilo 500 mg\/m2 i.V. Dia 1 y 8 + epirubicina 30 mg\/m2 i.V. Dia 1 y 8 o mitoxantrone 6 mg\/m2 i.V. Dia 1 y 8 cada cuatro semanas. Setenta y tres pacientes fueron elegibles para cef y 72 pacientes para cnf sin diferencias entre las caracteristicas de las pacientes en ambos grupos de tratamiento.  las respuestas objetivas conseguidas por cef (61,6%) fueron significativamente superiores a las conseguidas por cnf (45%)p:0,04. Las medianas del tiempo a la progresion (350 dias contra 236,5 dias,p:0,0016) y supervivencia (554,5 dias contra 384,5 dias, p:0,05) tambien han sido significativamente mas largas para la combinacion de cef.  la combinacion cnf fue mas mielotoxica (escala de la oms ; grados 2 a 4 : 85% contra 67% , p:0,02) pero el cef produjo mas alopecia (escala de la oms; grados 2 y 3: 93% contra 70%, p:0,0004). No hubo diferencias en la toxicidad cardiaca entre ambos grupos de tratamiento.  en conclusion: la combinacion de cef es mas activa y menos toxica que el cnf a excepcion de la alopecia en el tratamiento del carcinoma de mama avanzado de la mujer.<\/p>\n<p>&nbsp;<\/p>\n<h3>Datos acad\u00e9micos de la tesis doctoral \u00ab<strong>\u00abcomparacion entre la combinacion ciclofosfamida 4-epiadriamicina fluorouracilo (cef) y ciclofosfamida mitoxantrone. fluorouracilo (cnf) en el carcinoma avanzado de la mujer\u00bb.<\/strong>\u00ab<\/h3>\n<ul>\n<li><strong>T\u00edtulo de la tesis:<\/strong>\u00a0 \u00abcomparacion entre la combinacion ciclofosfamida 4-epiadriamicina fluorouracilo (cef) y ciclofosfamida mitoxantrone. fluorouracilo (cnf) en el carcinoma avanzado de la mujer\u00bb. <\/li>\n<li><strong>Autor:<\/strong>\u00a0 Emilio Esteban Gonzalez <\/li>\n<li><strong>Universidad:<\/strong>\u00a0 Oviedo<\/li>\n<li><strong>Fecha de lectura de la tesis:<\/strong>\u00a0 01\/01\/1994<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3>Direcci\u00f3n y tribunal<\/h3>\n<ul>\n<li><strong>Director de la tesis<\/strong>\n<ul>\n<li>Angel Jimenez Lacave<\/li>\n<\/ul>\n<\/li>\n<li><strong>Tribunal<\/strong>\n<ul>\n<li>Presidente del tribunal: Enrique Martinez Rodriguez <\/li>\n<li>Aurora Astudillo Gonzalez (vocal)<\/li>\n<li>Antonio Brugarolas Masllorens (vocal)<\/li>\n<li>\u00c1lvaro Ruibal Morell (vocal)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tesis doctoral de Emilio Esteban Gonzalez Desde diciembre de 1987 a junio de 1993, 151 pacientes fueron estratificadas segun la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[155,9,347,8846],"tags":[7918,9011,9012,8872,9010,8848],"class_list":["post-2104","post","type-post","status-publish","format-standard","hentry","category-ciencias-clinicas","category-ciencias-medicas","category-oncologia-clinica","category-oviedo","tag-alvaro-ruibal-morell","tag-angel-jimenez-lacave","tag-antonio-brugarolas-masllorens","tag-aurora-astudillo-gonzalez","tag-emilio-esteban-gonzalez","tag-enrique-Martinez-rodriguez"],"_links":{"self":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts\/2104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/comments?post=2104"}],"version-history":[{"count":0,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts\/2104\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/media?parent=2104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/categories?post=2104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/tags?post=2104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}